Target intelligence / Profile preview

Non-Helicobacter pylori gut microbiota

Molecular classification
Other
01

Overview

The non-Helicobacter pylori gut microbiota refers to the diverse community of microorganisms, including bacteria, archaea, fungi, and viruses, that inhabit the gastrointestinal tract excluding the H. pylori species. This complex ecosystem is essential for maintaining host homeostasis by facilitating the fermentation of non-digestible carbohydrates, synthesizing vitamins such as B12 and K, and providing a barrier against enteric pathogens (Source: Nature Reviews Microbiology, 2016). Beyond digestion, these microbes interact extensively with the host immune system, influencing both local and systemic inflammatory responses (Source: Science, 2017). Dysbiosis, or the imbalance of these microbial populations, has been implicated in the pathogenesis of numerous diseases, including inflammatory bowel disease (IBD), obesity, and Clostridioides difficile infection (Source: Cell, 2019). Therapeutic interventions targeting this microbiota include probiotics, prebiotics, and fecal microbiota transplantation (FMT), which aim to restore a healthy microbial balance (Source: The Lancet, 2017). Recent drug development efforts are also exploring postbiotics and small molecules that specifically modulate microbial metabolic pathways to treat metabolic and autoimmune disorders (Source: Nature Medicine, 2020).

Other names
Gut microbiomeIntestinal microbiotaNon-H. pylori gastric microbiotaCommensal gut floraGastrointestinal microbiota
02

Mechanism of action

Modulation of microbial community structure, restoration of commensal diversity, competitive inhibition of pathogens, and production of bioactive metabolites like short-chain fatty acids (SCFAs).

03

Biological functions

MetabolismImmune responsePathogen defenseVitamin synthesisSignal transduction
04

Disease associations

InfectionInflammationMetabolic syndromeCancerNeurodegenerative diseaseOther
05

Safety considerations

DysbiosisAntibiotic-associated diarrheaTransfer of antibiotic resistance genesSystemic infection in immunocompromised patients
06

Interacting drugs

Rifaximin

5 more in the full profile.

07

Biomarkers

Alpha diversity indexFirmicutes/Bacteroidetes ratioAkkermansia muciniphila abundanceFecal short-chain fatty acid levels

Beyond the preview

Go deeper on Non-Helicobacter pylori gut microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-Helicobacter pylori gut microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call